Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Invega in Schizophrenia
NCT01561898Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of paliperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Started Jun 2006; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01561898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561898.